🔴 Quantum BioPharma is trading 5.69% down in pre-market with no fresh company-specific catalyst identified

Quantum BioPharma is trading 5.69% down at $2.90 after no fresh company-specific catalyst was identified for August 31, 2026.

• Recent coverage centers on the August 10 FDA clearance for Lucid-MS Phase 2 and August 14 second-quarter results, making both developments stale explanations for today’s decline.
• Broader U.S. futures are modestly lower, but the market’s decline is below the threshold for a clear global explanation.
• Premarket volume and activity data were unavailable.